Note: Descriptions are shown in the official language in which they were submitted.
CA 02262401 1999-02-01
W O 98/05781 PCTAUS97/13603
SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
This application is a continuation-in-part of application Ser. No. 081691,641, filed
August 2, 1996, entitled "SECRETED PROTEINS AND POLYNUCLEOTIDES
ENCODING THEM", filed in the name of some or all of the inventors of the presentapplication.
FIELD OF THE INVENTION
The present invention provides novel polynucleotides and proteins encoded by such
polynucleotides, along with therapeutic, diagnostic and research utilities for these
polynucleotides and proteins.
BACKGROUND OF THE INVENTION
Technology aimed at the discovery of protein factors (including e.g., cytokines, such
as Iymphokines, i~ re~uns, CSFs and interleukins) has matured rapidly over the past decade.
The now routine hybridization cloning and expression cloning techniques clone novel
polynucleotides "directly" in the sense that they rely on information directly related to the
2 0 discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of
hybridization cloning; activity of the protein in the case of expression cloning). More recent
"indirect" cloning techniques such as signal sequen~e cloning, which isolates DNA sequences
based on the presence of a now well-recognized secretory leader sequence motif, as well as
various PCR-based or low stringency hybridization cloning techniques, have advanced the state
2 5 of the art by making available large numbers of DNA/amino acid sequences for proteins that
are known to have biological activity by virtue of their secreted nature in the case of leader
sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques.
It is to these proteins and the polynucleotides encoding them that the present invention is
directed.
SUMMARY OF THE INVENTION
In one embodiment, the present invention provides a composition comprising an
isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide COIl~p-isil~g the nucleotide sequence of SEQ ID
3 5 NO:2;
(b) a polynucleotide comI-n~ing the nucleotide sequence of SEQ ID NO:2
from nucleotide 309 to nucleotide 509;
CA 02262401 1999-02-01
WO 98/05781 PCTIUS97/13603
(c) a polynucleotide comprising the nucleotide sequence of the full length
protein coding sequence of clone BL15_12 deposited under accession number ATCC
98154;
(d) a polynucleotide encoding the full length protein encoded by the
cDNA insert of clone BL15_12 deposited under accession number ATCC 98154;
(e) a polynucleotide comprising the nucleotide sequence of the mature
protein coding sequence of clone BL15_12 deposited under accession number ATCC
98154;
(f) a polynucleotide encoding the mature protein encoded by the cDNA
1 0 insert of clone BL15_12 deposited under accession number ATCC g8154;
(g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID NO:3;
(h) a polynucleotide encoding a protein comprising a fragment of the
amino acid sequence of SEQ ID NO:3 having biological activity;
1 5 (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-
(d) above;
(j) a polynucleotide which encodes a species homologue of the protein
of (g) or (h) above .
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:22 0 from nucleotide 309 to nucleotide 509; the nucleotide sequence of the full length protein
coding sequence of clone BL15_12 deposited under accession number ATCC 98154; or the
nucleotide sequence of the mature protein coding sequence of clone BL15_12 deposited under
accession number ATCC 98154. In other preferred embodiments, the polynucleotide encodes
the full length or mature protein encoded by the cDNA insert of clone BL15_12 deposited
2 5 under accession number ATCC 98154.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID NO:2, SEQ ID NO: I or SEQ ID NO:4.
In altemate embodiments, isolate BL15_1 deposited under accession number ATCC
98117 may be substituted for BL15_12 in any of the foregoing.
In certain preferred embodiments, the polynucleotide is operably linked to an
expression control sequ~n~e The invention also provides a host cell, including bacterial, yeast,
insect and m~mm ~ n cells, transformed with such polynucleotide compositions.
Processes are also provided for producing a protein, which comprise:
~a) growing a culture of the host cell transforrned with such
3 5 polynucleotide co~l~po~ilions in a suitable culture medium; and
CA 02262401 1999-02-01
WO 98/05781 PCT/US97/13603
(b) purifying the protein from the culture.
The protein produced according to such methods is also provided by the present invention.
Preferred embodiments include those in which the protein produced by such process is a
mature form of the protein.
Protein compositions of the present invention may further comprise a pharmaceutically
acceptable carrier. Compositions comprising an antibody which specifically reacts with such
protein are also provided by the present invention.
Methods are also provided for preventing, treating or ameliorating a medical condition
which comprises ~flmini~rring to a m~mm~ n subject a therapeutically effective amount of
a composition comprising a protein of the present invention and a ph~ reutically acceptable
carrier.
DETAILED DESCRIPTION
~SOLATEDPROTEINS AND POLYNUCLEOT~DES
Nucleotide and amino acid sequences are reported below for each clone and protein
disclosed in the present application. In some in~t~nrÇ~ the sequences are preliminary and may
include some incorrect or ambiguous bases or amino acids. The actual nucleotide sequence
of each clone can readily be determined by sequencing of the deposited clone in accordance
2 0 with known methods. The predicted amino acid sequence (both full length and mature) can
then be determined from such nucleotide se4uence. The amino acid sequence of the protein
encoded by a particular clone can also be det~."~ ed by expression of the clone in a suitable
host cell, collecting the protein and determining its sequence.
For each disclosed protein applicants have id~ntifird what they have determined to be
2 5 the reading frame best identifiable with sequence information available at the time of filing.
Because of the partial ambiguity in reported seqllçnce inforrnation, reported protein sequences
include "Xaa" decign~tQrs. These "Xaa" dçsign~~ indicate either (1) a residue which cannot
be identified because of nucleotide sequçnre ambiguity or (2) a stop codon in the determined
nucleotide seqU~nre where applicants believe one should not exist (if the nucleotide sequence
3 0 were determined more accurately).
As used herein a "secreted" protein is one which, when expressed in a suitable host
cell, is transported across or through a membrane, including transport as a result of signal
sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins
secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they
CA 02262401 1999-02-01
WO 98/05781 PCTJUS97/13603
are expressed. "Secreted" proteins also include without limitation proteins which are
transported across the membrane of the endoplpasrnic reticulum.
Clone "BL15 12"
A polynucleotide of the present invention has been identified as clone "BL15_12".
BL15_12 was isolated from a human adult testes cDNA library using methods which are
selective for cDNAs encoding secreted proteins. BL15_12 is a full-length clone, including the
entire coding sequence of a secreted protein (also referred to herein as "BL15_12 protein").
The nucleotide sequence of the 5' portion of BL15_12 as presently deternined is
10 reported in SEQ ID NO:1. An additional internal nucleotide sequence from BLl5_12 as
presently determined is reported in SEQ ID NO:2. What applicants believe is the proper
reading frame and the predicted amino acid sequence encoded by such internal sequence is
reported in SEQ ID NO:3. Additional nucleotide sequence from the 3' portion of BL15_12,
including the polyA tail, is reported in SEQ ID NO:4.
The nucleotide sequence disclosed herein for BL15_12 was searched against the
GenBank database using BLASTAIBLASTX and FASTA search protocols. No hits were
found in the (l~ h~ce.
Deposit of Clones
Clone BL15_12 was deposited on August 23, 1996 with the American Type Culture
Collection under accession number 98154.
An additional isolate of BL15, BL15_1, was deposited on July 9, 1996 with the
2 5 American Type Culture Collection as part of a co",posit~ deposit (with other clones) under
accession number ATCC 98117, from which the clone is obtainable.
Each clone has been transfected into separate bacterial cells (E. coli) in this composite
deposit. Each clone can be removed from the vector in which it was deposited by performing
an EcoRI/NotI digestion (5' cite, EcoRI; 3' cite, NotI) to produce the appropriate fragment for
3 0 such clone. Bacterial cells containing a particular clone can be obtained from the composite
deposit as follows:
An oligonucleotide probe or probes should be ~l~cigned to the seq~ence that is known
for that particular clone. This sequence can be derived from the sequences provided herein,
or from a cu,l-bi~ ion of those sequences. The sequence of the oligonucleotide probe that was
CA 02262401 1999-02-01
WO 98/05781 PCTJUS97113603
used to isolate each full-length clone is identified below, and should be most reliable in
isolating the clone of interest.
Clone Probe Sequence
5 BL15_12 SEQ ID NO:S
In the sequences listed above which include an N at position 2, that position is occupied in
preferred probes/primers by a biotinylated phosphoaramidite residue rather than a nucleotide
(such as, for exarnple, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-
1 0 2-(N-biotinyl-4-aminobutyl)-propyl-3-0-(2-cyanoethyl~-(N,N-diisopropyl)-phosphoramadite)
(Glen Research, cat. no. 10-1953)).
The design of the oligonucleotide probe should preferably follow these parameters:
(a) It should be designed to an area of the sequence which has the fewest
ambiguous bases ("N's"), if any;
(b) It should be designed to have a Tm of approx. 80 c C (~sllming 2~ for each A or T and 4 degrees for each G or C).
The oligonucleotide should preferably be labeled with g 32p ATP (specific activity 6000
Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling
2 0 oligonucleotides. Other labeling techniques can also be used. Unincorporated label should
preferably be removed by gel filtration chromatography or other established methods. The
amount of radioactivity incorporated into the probe should be quantitated by measurement in
a scintillation counter. Preferably, specific activity of the resulting probe should be
approximately 4e+6 dpm/pmole.
2 5 The bacterial culture containing the pool of full-length clones should preferably be
thawed and 100 111 of the stock used to inoculate a sterile culture flask containing 25 ml of
sterile L-broth c~,"~ hlg ~mp;~illin at 100 ~lg/ml. The culture should preferably be grown to
saturation at 37~C, and the saturated culture should preferably be diluted in fresh L-broth.
Aliquots of these dilutions should preferably be plated to determine the dilution and volume
3 0 which will yield approximately 5000 distinct and well-separated colonies on solid
bacteriological media containing L-broth containing ampicillin at 100 ~lg/ml and agar at 1.5%
in a 150 mm petri dish when grown overnight at 37~C. Other known methods of obtaining
distinct, well-separated colonies can also be employed.
Standard colony hybridization procedures should then be used to transfer the colonies
3 5 to nitrocellulose filters and Iyse, denature and bake them.
CA 02262401 1999-02-01
WO 98105781 PCT/US97/13603
The filter is then preferably incubated at 65~C for I hour with gentle agitation in 6X
SSC (20X stock is }7~.3 g NaCI/liter, 8~.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH)
containing 0.5% SDS, 100 ,ug/ml of yeast RNA, and 10 mM ~DTA (approximately 10 mL per
1~0 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration
5 greater than or equal to le+6 dpmlmL. The filter is then preferably incubated at 65~C with
gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5%
SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1%
SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X
SSC10.5% SDS at 65~C for 30 rninutes to 1 hour is optional. The filter is then preferably dried
10 and subjected to autoradiography for sufficient time to visuali~e the positives on the X-ray
film. Other known hybridization methods can also be employed.
The positive colonies are picked, grown in culture, and plasmid DNA isolated using
standard procedures. The clones can then be verified by restriction analysis, hybridization
analysis, or DNA sequencing.
Fragments of the proteins of the present invention which are capable of exhibiting
biological activity are also encompassed by the present invention. Fragments of the protein
may be in linear form or they may be cyclized using known methods, for example, as described
2 0 in H.U. Saragovi, ef al., Bio/Technology 10, 773-778 (1992) and in R.S. McDowell, et al., J.
Amer. Chem. Soc. 114, 9245-9253 (199~), both of which are incorporated herein by reference.
Such fragments may be fused to carrier molecules such as immunoglobulins for many
purposes, including increasing the valency of protein binding sites. For example, fragments
of the protein may be fused through "linker" sequences to the Fc portion of an
2 5 immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion
of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such
fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein
of the invention.
The present invention also provides both full-length and mature forms of the disclosed
3 0 proteins. The full-length form of the such proteins is id~ntified in the se~uence listing by
translation of the nucleotide sequence of each disclosed c10ne. The mature form of such
protein may be obtained by expression of the disclosed full-length polynucleotide (preferably
those deposited with ATCC) in a suitable m~mm~ n cell or other host cell. The sequence of
the mature form of the protein may also be determinable from the amino acid sequence of the
3 5 full-length form.
CA 02262401 1999-02-01
W O 98/05781 PCTAUS97/13603
The present invention also provides genes corresponding to the cDNA sequences
disclosed herein. The corresponding genes can be isolated in accordance with known methods
using the sequence information disclosed herein. Such methods include the preparation of
probes or primers from the disclosed sequence information for identification and/or
amplification of genes in appropriate genomic libraries or other sources of genomic materials.
Where the protein of the present invention is membrane-bound (e.g., is a receptor), the
present invention also provides for soluble forms of such protein. In such forms part or all of
the intracellular and transmembrane domains of the protein are deleted such that the protein
is fully secreted from the cell in which it is expressed. The intracellular and transmembrane
domains of proteins of the invention can be identified in accordance with known techniques
for determination of such domains from sequence information.
Species homologs of the disclosed polynucleotides and proteins are also provided by
the present invention. Species homologs may be isolated and identified by making suitable
probes or primers from the sequences provided herein and screening a suitable nucleic acid
source from the desired species.
The invention also encompasses allelic variants of the disclosed polynucleotides or
proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also
encode proteins which are identical, homologous or related to that encoded by the
polynucleotides .
2 0 The isolated polymtcleotide of the invention may be operably linked to an expression
control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al.,
Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly.
Many suitable expression control sequences are known in the art. General methods of
expressing recolllbi~ proteins are also known and are exemplified in R. Kaufman, Methods
in Enzymology 185, 537-566 (1990). As defined herein "operably linked" means that the
isolated polymlcleoti~ of the invention and an expression control sequenre are situated within
a vector or cell in such a way that the protein is expressed by a host cell which has been
transformed (transfected) with the ligated polynucleotidelexpression control sequence.
A number of types of cells may act as suitable host cells for expression of the protein.
3 0 M~rnm~ n host cells include, for example, monkey COS cells, Chinese Hamster Ovary
(CHO) cells, human kidney 293 cells, human epidermal A43 I cells, human Colo20~ cells, 3T3
cells, CV-1 cells, other ~ rolllled primate cell lines, norrnal diploid cells, cell strains derived
from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-
60, U937, HaK or Jurkat cells.
CA 02262401 1999-02-01
WO 98105781 PCT/US97/13603
Alternatively, it may be possible to produce the protein in lower eukaryotes such as
yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include
Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kll~yveromyces strains, Can~ida, or
any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial
5 strains include Escherichia coli, Bacillus sul~tilis, Salmo~ellu typhim~lrium, or any bacterial
strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria,
it may be necessary to modify the protein produced therein, for example by phosphorylation
or glycosylation of the appropriate sites, in order to obtain the functional protein. Such
covalent attachments may be accomplished using known chemical or enzymatic methods.
The protein may also be produced by operably linking the isolated polynucleotide of
the invention to suitable control sequences in one or more insect expression vectors, and
employing an insect expression system. Materials and methods for baculovirus/insect cell
expression systems are commercially available in kit form from, e.~., Invitrogen, San Diego,
California, U.S.A. (the MaxBac(~ kit), and such methods are well known in the art, as
15 described in Summers and Smith, Texas A~ricultural Experiment Station Bulletin No. 1~
(1987), incorporated herein by reference. As used herein, an insect cell capable of expressing
a polynucleotide of the present invention is "transformed."
The protein of the invention may be prepared by c~ nnng transformed host cells under
culture conditions suitable to express the recombinant protein. The resulting expressed protein
2 0 may then be purified from such culture (i.e., from culture medium or cell extracts) using known
purification processes, such as gel filtration and ion exchange chromatography. The
purification of the protein may also include an affinity column containing agents which will
bind to the protein; one or more column steps over such affinity resins as concanavalin A-
agarose, heparin-toyopearl~) or Cibacrom blue ~GA S~h~osc~3; one or more steps involving
2 5 hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or
propyl ether; or immunoaffinity chromatography.
Alternatively, the protein of the invention may also be expressed in a form which will
facilitate purification. For example, it may be expressed as a fusion protein, such as those of
maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits
3 0 for expression and purification of such fusion proteins are commercially available from New
England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and InVitrogen, respectively.
The protein can also be tagged with an epitope and subsequently purified by using a specific
antibody directed to such epitope. One such epitope ("Flag") is commercially available from
Kodak (New Haven, CT).
CA 02262401 1999-02-01
W O 98/05781 PCT~US97/13603
Finally, one or more reverse-phase high performance liquid chromatography (RP-
HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl
or other aliphatic groups, can be employed to further purify the protein. Some or all of the
foregoing purification steps, in various combinations. can also be employed to provide a
substantially homogeneous isolated recombinant protein. The protein thus purified is
substantially free of other m~mm:~1ian proteins and is defined in accordance with the present
invention as an "isolated protein."
The protein of the invention may also be expressed as a product of transgenic animals,
e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are
ch~ra~ 7~d by somatic or germ cells containing a nucleotide sequence encoding the protein.
The protein may also be produced by known conventional chemical synthesis.
Methods for constructing the proteins of the present invention by synthetic means are known
to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing
primary, secondary or tertiary structural and/or conforrnational characteristics with proteins
may possess biological properties in common therewith, including protein activity. Thus, they
may be employed as biologically active or immunological substitutes for natural, purified
proteins in screening of therapeutic compounds and in immunological processes for the
development of antibodies.
The proteins provided herein also include proteins characterized by amino acid
2 0 sequences similar to those of purified proteins but into which modification are naturally
provided or deliberately engineered. For example, modifications in the peptide or DNA
sequences can be made by those skilled in the art using known techniques. Modifications of
interest in the protein sequences may include the alteration, substitution, replacement, insertion
or deletion of a selected amino acid residue in the coding sequence. For example, one or more
2 5 of the cysteine residues may be deleted or replaced with another amino acid to alter the
conformation of the molecule. Techniques for such alteration, substitution, repl~çmPnt,
insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No.
4,518,584). Preferably, such alteration, ~ub~lilulion, repl~-~em.-nt, insertion or deletion retains
the desired activity of the protein.
3 0 Other fragments and derivatives of the seqn~nces of proteins which would be expected
to retain protein activity in whole or in part and may thus be useful for screening or other
immunological methodologies may also be easily made by those skilled in the art given the
disclosures herein. Such modifications are believed to be encomp~sed by the present
invention.
CA 02262401 1999-02-01
WO 98/05781 PCT/US97/13603
USES AND BIOLOGICAL ACTIVITY
l he polynucleotides and proteins of the present invention are expected to exhibit one
or more of the uses or biological activities (including those associated with assays cited herein)
identified below. Uses or activities described for proteins of the present invention may be
5 provided by administration or use of such proteins or by administration or use of
polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors
suitable for introduction of DNA).
Research Uses and Utilities
The polynucleotides provided by the present invention can be used by the research
community for various purposes. The polynucleotides can be used to express recombinant
protein for analysis, char~rt~ri7~tion or therapeutic use; as markers for tissues in which the
culJt;~c,nding protein is preferentially expressed (either constitutively or at a particular stage
of tissue ~liffel~ .Lion or development or in disease states); as molecular weight markers on
15 Southern gels; as chrûmosome markers or tags (when labeled) to identify chromosomes or to
map related gene positions; to compare with endogenous DNA sequences in patients to identify
potential genetic disorders; as probes to hybridize and thus discover novel, related DNA
sequences; as a source of inforrnation to derive PCR primers for genetic fingerprinting; as a
probe to "subtract-out" known sequences in the process of discovering other novel
2 0 polynucleotides; for selecting and making oligomers for ~tt~rhmPnt to a "gene chip" or other
support, including for examination of expression patterns; to raise anti-protein antibodies using
DNA i""~ ion techniques; and as an antigen to raise anti-DNA antibodies or elicit
another immune response. Where the polynucleotide encodes a protein which binds or
potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the
2 5 polynucleotide can also be used in interaction trap assays (such as, for example, that described
in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein
with which binding occurs or to identify inhibitors of the binding interaction.
The proteins provided by the present invention can similarly be used in assay todetermine biological activity, including in a panel of multiple proteins for high-throughput
3 0 screening; to raise antibodies or to elicit another immune response; as a reagent (including the
labeled reagent) in assays dP~igned to quantitatively determine levels of the protein (or its
receptor) in biological fluids; as markers for tissues in which the cullc~,onding protein is
pl~f~lelllially expressed (either constitutively or at a particular stage of tissue differentiation
or development or in a disease state~; and, of course, to isolate correlative receptors or ligands.
3 5 Where the protein binds or potentially binds to another protein (such as, for example, in a
CA 02262401 1999-02-01
WO 98/05781 PCT/US97113603
receptor-ligand interaction), the protein can be used to identify the other protein with which
binding occu;s or to identify inhibitors of the binding interaction. Proteins involved in these
binding interactions can also be used to screen for peptide or small molecule inhibitors or
agonists of the binding interaction.
Any or all of these ;esearch utilities are capable of being developed into reagent grade
or 'Kit format for commercialization as research products.
Methods for performing the uses listed above are well known to those skilled in the
art. References disclosing such methods include without limitation "Molecular Cloning: A
Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch
and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning
Techniques", Academic Press, Berger, S.L. and A.~. Kimmel eds., 1987.
Nutritional Uses
Polynucleotides and proteins of the present invention can also be used as nutritional
sources or supplements. Such uses include without limitation use as a protein or amino acid
supplement, use as a carbon source, use as a nitrogen source and use as a source of
carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the
feed of a particular organism or can be administered as a separate solid or liquid plepdl~liOn,
such as in the form of powder, pills, solutions, suspensions or capsules. In the case of
2 0 micro~ C, the protein or polynucleotide of the invention can be added to the medium
in or on which the microorganism is cultured.
Cytokine and Cell Proliferation/Dirl~.cntiation Activity
A protein of the present invention may exhibit cytokine, cell proliferation (either
2 5 inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may
induce production of other cytokines in certain cell populations. Many protein factors
discovered to date, including all known cytokines, have exhibited activity in one or more factor
dependent cell proliferation assays, and hence the assays serve as a convenient confirmation
of cytokine activity. The activity of a protein of the present invention is evidenced by any one
3 0 of a number of routine factor dependent cell proliferation assays for cell lines including,
without liinitation, 32D, DA2, DAlG, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E~,
RBS, DAl, 123, T1165, HT2, CTLL2, TF-l, Mo7e and CMK.
The activity of a protein of the invention may, among other means, be measured by the
following methods:
CA 02262401 1999-02-01
WO 98/05781 PCT/[JS97/13603
Assays for T-cell or thymocyte proliferation include without limitation those described
in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies,
E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter
3, In Vitro assays for Mouse Lymphocyte Function 3.1 -3. I g; Chapter 7, Immunologic studies
in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol.
145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991;
Bertagnolli, et al., J. Immunol. 149:3778-3783, I 992; Bowman et al., J. Immunol. 15'~: 1756-
1761, 1994.
Assays for cytokine production and/or proliferation of spleen cells, Iymph node cells
1 0 or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation,
Kruisbeek, A.M. and Shevach, E.M. In Current Protocols in ~mmunology. J.E.e.a. Coligan
eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. Ig94; and Measurement of
mouse and human Int~lre~ , Schreiber, R.D. In Current Protocols in Immlmology. J.E.e.a.
Coligan eds. Vol I pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.
Assays for proliferation and differentiation of hematopoietic and Iymphopoietic cells
include, without limitation, those described in: Measurement of Human and Murine Interleukin
2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In Current Prolocols in
Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto.
1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692,
2 0 1988; Gree,.bel~l et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931 -2938, 1983; Measurement of
mouse and human interleukin 6 - Nordan, R. In Current Protocols in Immunology. J.E.e.a.
Coligan eds. Vol 1 pp. 6.6.1-6.6.~, John Wiley and Sons, Toronto. 1991; Smith et al., Proc.
Natl. Acad. Sci. U.S.A.83: 1857-1861, 1986; Measurement of human Interleukin 11 - Bennett,
F., Giannotti, J., Clark, S.C. and Turner, K. J. In Current Protocols in Immunology. J.E.e.a.
2 5 Coligan eds. Vol I pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Mea~,ul~ll,cllt of mouse
and human Interleukin 9 - Ciarletta, A., Giannotti, J., C}ark, S.C. and Turner, K.J. In Current
Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons,
Toronto. 1991.
Assays for T-cell clone responses to antigens (which will identify, among others,
3 0 proteins that affect APC-T cell interactions as well as direct T-cell effects by me:~c-lnng
proliferation and cytokine production) include, without limitation, those described in: Current
Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M.
Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3,
In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular
3 5 receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad.
12
CA 02262401 1999-02-01
WO 98105781 PCT/US97/13603
Sci. USA 77:6091-6095, 1980; Weinbergeretal., ~ur. J. Immun. 11:405-411, 1981; Takai
et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:~08-512, 1988.
Immune Stimulatin~ or ~uppressin~ Activity
A protein of the present invention may also exhibit immune stimulating or immunesuppressing activity, including without limitation the activities for which assays are described
herein. A protein may be useful in the treatment of various immune deficiencies and disorders
(including severe combined immunodeficiency (SCID)), e.g., in regulating (up o} down)
growth and proliferation of T and/or B Iymphocytes, as well as effecting the cytolytic activity
1 0 of NK cells and other cell populations. These immune deficiencies may be genetic or be
caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from
autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal
or other infection may be treatable using a protein of the present invention, including
infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Lei~hm~ni~ spp., malaria
1 5 spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of
the present invention may also be useful where a boost to the immune system generally may
be desirable, i.e., in the treatment of cancer.
Autoimmune disorders which may be treated using a protein of the present invention
include, for example, connective tissue disease, multiple sclerosis, systemic lupus
2 0 erythem~tosll~, rheum~oid arthritis, autoimmune pulmonary inflammation, Guillain-Barre
syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis,
graft-versus-host disease and autoimmune infl lmm~tory eye disease. Such a protein of the
present invention may also to be useful in the treatment of allergic reactions and conditions,
such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions,
2 5 in which immune su~ s~ion is desired (including, for example, organ transplantation), may
also be treatable using a protein of the present invention.
Using the proteins of the invention it may also be possible to immune responses, in a
number of ways. Down regulation may be in the form of inhibiting or blocking an immune
response already in progress or may involve preventing the induction of an immune response.
3 0 The functions of activated T cells may be inhibited by suppressing T cell responses or by
inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is
generally an active, non-antigen-specific, process which requires continuous exposure of the
T cells to the ~u~pl~s~ive agent. Tolerance, which involves inducing non-responsiveness or
anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-
3 5 specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance
13
. .
CA 02262401 1999-02-01
WO 98/05781 PCTIUS97113603
can be demonstrated by the lack of a T cell response upon reexposure to specihc antigen in the
absence of the tolerizing agent.
Down regulating or preventing one or more antigen functions (including without
limitation B Iymphocyte antigen functions (such as, for example, B7)), e.,~., preventing high
5 level Iymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and
organ transplantation and in graft-versus-host disease (GV~D). For example, blockage of T
cell function should result in reduced tissue destruction in tissue transplantation. Typically,
in tissue transplants, rejection of the transplant is initiated through its recognition as foreign
by T cells, followed by an immune reaction that destroys the transplant. The administration
1 0 of a molecule which inhibits or blocks interaction of a B7 Iymphocyte antigen with its natural
ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2
activity alone or in conjunction with a monomeric form of a peptide having an activity of
another B Iymphocyte antigen (e.g., B7-1, B7-3) or blocking antibody), prior to transplantation
can lead to the binding of the molecule to the natural ligand(s) on the immune cells without
1 5 ~ Ui~g the corresponding cos~iml-l~t~ry signal. Blocking B Iymphocyte antigen function
in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an
immuno~upplessant. Moreover, the lack of costimulation may also be sufficient to anergize
the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B
Iymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of
2 0 these blocking reagents. To achieve sufficient immuno~u~p,t:s~ion or tolerance in a subject,
it may also be necessary to block the function of a combination of B Iymphocyte antigens.
The ef~lcacy of particular blocking reagents in preventing organ transplant rejection
or GVHD can be assessed using animal models that are predictive of efficacy in humans.
Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats
2 5 and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine
the immuno~u~lcssive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow
el al., Science 257:789-792 (1992) and Turka et al., Proc. Natl. Acad. Sci USA, 89:11102-
11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundarnental Immunology,
Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking
3 0 B Iymphocyte antigen function in vivo on the development of that disease.
Blocking antigen function may also be lI~1APe~ Y useful for treating autoimmune
flicc~çs Many aUIoi~ ulle disorders are the result of inapp,ul,.iate activation of T cells that
are reactive against self tissue and which promote the production of cytokines and
autoantibodies involved in the pathology of the rlicP~es Preventing the activation of
3 5 autoreactive T cells may reduce or eliminate disease symptoms. ~lTnini~tration of reagents
14
CA 02262401 1999-02-01
WO 98/0~781 PCT/US97113603
which block coslim~ ion of T cells by disrupting receptor:ligand interactions of B
Iymphocyte antigens can be used to inhibit T cell activation and prevent production of
autoantibodies or T cell-derived cytokines which may be involved in the disease process.
Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells
5 which could lead to long-term relief from the disease. The efficacy of blocking reagents in
preventing or alleviating autoimmune disorders can be determined using a number of well-
characterized animal models of human autoimmune diseases. Examples include murine
experimental autoimmune encephalitis, systemic lupus ery~hm~toci~ in MRLIIpr/lpr mice or
NZB hybrid mice, murine ~-ltoimmllne collagen arthritis, diabetes mellitus in NOD mice and
10 BB rats, and murine experimental myasthenia gravis (see Paul ed., Fnnrl~mf n~l Immunology,
Raven Press, New York, 1989, pp. 840-856).
Upregulation of an antigen function (preferably a B Iymphocyte antigen function), as
a means of up regulating immune responses, may also be useful in therapy. Upregulation of
immune responses may be in the form of enhancing an existing immune response or eliciting
15 an initial immune response. For example, enhancing an immune response through stim~ ting
B Iymphocyte antigen function may be useful in cases of viral infection. In addition, systemic
viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the
administration of s~imnl~t~-ry forms of B Iymphocyte antigens systemically.
Alternatively, anti-viral immune responses may be enh~nced in an infected patient by
2 0 removing T cells from the patient, costimul~ling the T cells in vitro with viral antigen-pulsed
APCs either expressing a peptide of the present invention or together with a stimulatory form
of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into
the patient. Another method of enhancing anti-viral immune responses would be to isolate
infected cells from a patient, transfect them with a nucleic acid encoding a protein of the
2 5 present invention as described herein such that the cells express all or a portion of the protein
on their surface, and reintroduce the transfected cells into the patient. The infected cells would
now be capable of delivering a cosrim--l~tory signal to, and thereby activate, T cells in vivo.
In another application, up regulation or çnh~n~ement of antigen function (preferably
B Iymphocyte antigen function) may be useful in the induction of tumor h~ lu~ y. Tumor
3 0 cells (e.g., sarcoma, melanoma, Iymphoma, lenk(çmi:l, neuroblastoma, carcinoma) transfected
with a nucleic acid encoding at least one peptide of the present invention can be administered
to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can
be transfected to express a culllbi~ld~ion of peptides . For example, tumor cells obtained from
a patient can be transfected ex vivo with an expression vector directing the expression of a
3 5 peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like
CA 02262401 1999-02-01
WO 98/05781 PCT/US97/13603
activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to
result in expression of the peptides on the surface of the transfected cell. Alternatively, gene
therapy techniques can be used to target a tumor cell for transfection in vivo.
The presence of the peptide of the present invention having the activity of a B
5 Iymphocyte antigen(s) on the surf~ce of the tumor cell provides the necessary costimulation
signal to T cells to induce a T cell mediated immune response against the transfected tumor
cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which
fail to reexpress suf~lcient amounts of MHC class I or MHC class II molecules, can be
transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated
1 0 portion) of an MHC class I a chain protein and ,B2 microglobulin protein or an MHC class II
a chain protein and an MHC class II ,B chain protein to thereby express MHC class I or MHC
class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in
conjunction with a peptide having the activity of a B Iymphocyte antigen (e.g., B7-1, B7-2, B7-
3) induces a T cell mP~ t~d immune response against the transfected tumor cell. Optionally,
1 5 a gene encoding an ~nti~en~e construct which blocks expression of an MHC class II ~ccoci~
protein, such as the invariant chain, can a}so be cotransfected with a DNA encoding a peptide
having the activity of a B Iymphocyte antigen to promote presentation of tumor associated
antigens and induce tumor specific immunity. Thus, the induction of a T cell m.~ ted
immune response in a human subject may be sufficient to overcome tumor-specific tolerance
2 0 in the subject.
The activity of a protein of the invention may, among other means, be measured by the
following methods:
Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation,
those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek,
2 5 D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-
Interscience (Chapter 3, In Vitro assays for Mouse ~ymphocyte Function 3.1-3.19; Chapter 7,
Immunologic studies in Humans); H~ nn et al., Proc. Natl. Acad. Sci. USA 78:2488-2492,
1981; Ilcl,,,,a.ln et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol.
135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J.
3 0 Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492,
1981; Hernnann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol.
135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowmanet al., J.
Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al.,
CellularImmunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.
16
CA 02262401 1999-02-01
W O 98105781 PCTAUS97/13603
Assays for T-cell-depen~lent immunoglobulin responses and isotype switching (which
will identify, among others, proteins that modulate T-cell dependent antibody responses and
that affect Thl/Th2 profiles) include, without limitation, those described in: Maliszewski, J.
Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production,
Mond, J.J. and Brunswick, M. In Current Protocols ln Immunology. J.E.e.a. Coligan eds. Vol
I pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.
Mixed Iymphocyte reaction (MLR) assays (which will identify, among others, proteins
that generate predominantly Thl and CTL responses) include, without limitation, those
described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H.
Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1 -3.19; Chapter 7,
Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al.,
J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.
Dendritic cell-dependent assays (which will identify, among others, proteins expressed
by dendritic cells that activate naive T-cells) include, without limitation, those described in:
Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine
173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071 -5079, 1995; Porgador
et al., Joumal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology
67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of
2 0 Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical
Investigation 94:797-807, 1994; and Inaba et al., Joumal of Experimental Medicine 172:631 -
640, 1990.
Assays for Iymphocyte survival/~uplosis (which will identify, among others, proteins
that prevent apoptosis after superantigen induction and proteins that regulate Iymphocyte
2 5 homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry
13:795-808, 1992; Gorczyca et al., ~.eukf rni~ 7:659-670, 1993; Gorczyca et al., Cancer
Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of
Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et
al., TntPrn~tional Journal of Oncology I :639-648, 1992.
3 0 Assays for proteins that inflllence early steps of T-cell commitment and development
include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine
et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Tûki
et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.
3 5 Hematopoiesis Re~ulating Activity
17
CA 02262401 1999-02-01
W 0 98105781 PCTAJS97113603
A protein of the present invention may he useful in regulation of hematopoiesis and,
consequently, in the treatment of myeloid or Iymphoid cell deficiencies. ~ven marginal
biological activity in support of colony forming cells or of factor-dependent cell lines indicates
involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of
erythroid progenitor cells alone or in combination with other cytokines, thereby indicating
utility, for example, in treating various anemias or for use in conjunction withi~Tadiationlchemotherapy to stimulate the production of erythroid precursors and/or erythroid
cells; in supporting the growth and proliferation of myeloid cells such as granu]ocytes and
monocytes/macrophages (i.e., traditional CSF activity) usefu], for example, in conjunction with
1 0 chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and
proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or
Lll.c;l.t of various platelet disorders such as thrombocytopenia, and generally for use in place
of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation
of hematopoietic stem cells which are capable of maturing to any and all of the above-
mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell
disorders (such as those usually treated with transplantation, including, without limitation,
aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem
cell coln~ --t post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction
with bone marrow transplantation or with peripheral progenitor cell transplantation
2 0 (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.
The activity of a protein of the invention may, among other means, be measured by the
following methods:
Suitable assays for proliferation and dirr~ ~--liation of various hematopoietic lines are
cited above.
Assays for embryonic stem cell differentiation (which will identify, among others,
proteins that influence embryonic difr~ iation hematopoiesis) include, without limitation,
thosedescribedin:Joha,.ss-~netal.CellularBiology 15:141-151, 1995;Kelleretal.,Molecular
and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.
Assays for stem cell survival and difre.el~liation (which will identify, among others,
3 0 proteins that regulate Iympho-hematopoiesis) include, without limitation, those described in:
Methylcellulose colony forming assays, Freshney, M.G. In Culture of Hematopoietic Cells. R.I.
Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et
al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming
cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In Culture of
3 5 f~ematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York,
18
CA 02262401 1999-02-01
W O 98tO5781 PCT~US97113603
NY. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area
forrning cell assay, Ploemz-~~~er, R.E. In Cl~lture of Hematopoietic Cells. R.I. Freshney, et al.
eds. Vol pp. I -21, Wiley-Liss, Inc.., New York, NY. ] 994; Long term bone marrow cultures
in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of
Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York,
NY.1994; Long term culture initiating cell assay, Sutherland, H.J. In Culture of Hematopoietic
Cells. R.I. Freshney, et al. eds. Vol pp. 13g-162, Wiley-Liss, Inc., New York, NY. 1994.
Tissue Growth Activity
1 0 A protein of the present invention also may have utility in compositions used for bone,
cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound
healing and tissue repair and replacement, and in the ll~d~llJent of burns, incisions and ulcers.
A protein of the present invention, which induces cartilage and/or bone growth in
circumstances where bone is not normally formed, has application in the healing of bone
fractures and cartilage damage or defects in humans and other animals. Such a preparation
employing a protein of the invention may have prophylactic use in closed as well as open
fracture reduction and also in the improved fixation of artificial joints. De novo bone
formation induced by an osteogenic agent contributes to the repair of congenital, trauma
induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic
2 0 plastic surgery.
A protein of this invention may also be used in the lle~lnlc..l of periodontal disease,
and in other tooth repair processes. Such agents may provide an environment to attract bone-
forming cells, stim~ t~ growth of bone-forming cells or induce differentiation of progenitors
of bone-forming cells. A protein of the invention may also be useful in the treatment of
2 5 osteoporosis or osteoarthritis, such as through stim~ tion of bone and/or caTtilage repair or by
blocking infl:~mm~tion or processes of tissue destruction (collagenase activity, osteoclast
activity, etc.) ml~ t~d by infl~mm~tclry processes.
Another category of tissue regeneration activity that may be attributable to the protein
of the present invention is tendon/ligament formation. A protein of the present invention,
- 3 0 which induces tendon/ligament-like tissue or other tissue formation in circumstances where
such tissue is not normally formed, has application in the healing of tendon or ligament tears,
deformities and other tendon or ligament defects in humans and other animals. Such a
pl~l~aldlion employing a tendon/ligament-like tissue inducing protein may have prophylactic
use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation
3 5 of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament
19
CA 02262401 1999-02-01
WO 98/05781 PCT/US97113603
tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present
invention c~n~ es to the repair of congenital, trauma induced, or other tendon or ligament
defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair
of tendons or ligaments. The compositions of the present invention may provide an
5 environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or
ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming
cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to
effect tissue repair. The compositions of the invention may also be useful in the treatment of
tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions
10 may also include an appropriate matrix and/or sequestering agent as a carrier as is well known
in the art.
The protein of the present invention may also be useful for proliferation of neural cells
and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral
nervous system diseases and neuropathies, as well as mechanical and traumatic disorders,
15 which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically,
a protein may be used in the treatment of diseases of the peripheral nervous system, such as
peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central
nervous system diseases, such as ~17h~im~r's, Parkinson's disease, Huntington's disease,
amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be
2 0 treated in accordance with the present invention include m.och:lnical and traumatic disorders,
such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke.
Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be
treatable using a protein of the invention.
Proteins of the invention may also be useful to promote better or faster closure of non-
2 5 healing wounds, including without limitation pressure ulcers, ulcers associated with vascularinsufficiency, surgical and traumatic wounds, and the like.
It is expected that a protein of the present invention may also exhibit activity for
generation or regeneration of other tissues, such as organs (including, for example, pancreas,
liver, inteStin~ kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular
3 0 (including vascular endothelium) tissue, or for promoting the growth of cells comprising such
tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to
allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic
activity.
CA 02262401 1999-02-01
WO 98/05781 PCT/US97/13603
A protein of the present invention may also be useful for gut protection or regeneration
and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions
resulting from systemic CytoKine damage.
A protein of the present invention may also be useful for promoting or inhibiting
5 differentiation of tissues described above from precursor tissues or cells; or for inhibiting the
growth of tissues described above.
The activity of a protein of the invention may, among other means, be measured by the
fol]owing methods:
Assays for tissue generation activity include, without limitation, those described in:
International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International
Patent Publicalion No. WO95/05846 (nerve, neuronal); International Patent Publication No.
WO91/07491 (skin, endothelium ).
Assays for wound healing activity include, without limitation, those described in:
Winter, Epidermal Wound Healin,e~ pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year
15 Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest.
Dermatol 71:382-84 (1978).
Activin/Inhibin Activity
A protein of the present invention may also exhibit activin- or inhibin-related
2 0 activities. Inhibins are char~t~.ri7~d by their ability to inhibit the release of follicle stim~ ting
hormone (FSH), while activins and are characterized by their ability to stimulate the release
of follicle stimul~ting hormone (FSH). Thus, a protein of the present invention, alone or in
heterodimers with a member of the inhibin ~ family, may be useful as a contraceptive based
on the ability of inhibins to decrease fertility in female mslmm~lc and decrease spermatogenesis
2 5 in male m~mm~lc A-lminictration of sufficient amounts of other inhibins can induce infertility
in these m~mm~lc Alternatively, the protein of the invention, as a homodimer or as a
heterodimer with other protein subunits of the inhibin-,B group, may be useful as a fertility
inducing therapeutic, based upon the ability of activin molecules in 5rim~ tine FSH release
from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A
3 0 protein of the invention may also be useful for advancement of the onset of fertility in sexually
imm~tllre m:~mm llC, SO as to increase the lifetime reproductive performance of domestic
animals such as cows, sheep and pigs.
The activity of a protein of the invention may, among other means, be measured by the
following methods:
CA 02262401 1999-02-01
W O 98/05781 PCT~US97/13603
Assays for activin/inhibin activity include, without limitation, those described in: Vale
et al., Endocrinology 91 :562-572, 1972; Ling et ah, Nature 321 :779-782, 1986; Vale et al.,
Nature 321:776-779,1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl.
Acad. Sci. USA 83:3091-3095, 1986.
ChemotacticlChemokinetic Activity
A protein of the present invention may have chemotact~c or chemokinetic activity (e.g.,
act as a chemokine) for m~mm~ n cells, including, for example, monocytes, fibroblasts,
neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic
1 0 and chemokinetic proteins can be used to mobilize or attract a desired cell population to a
desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in
treatment of wounds and other trauma to tissues, as well as in treatment of localized infections.
For example, attraction of Iymphocytes, monocytes or neutrophils to tumors or sites of
infection may result in improved immune responses against the tumor or infecting agent.
1 5 A protein or peptide has chemotactic activity for a particular cell population if it can
c~im~ t~ directly or indirectly, the directed orientation or movement of such cell population.
Preferably, the protein or peptide has the ability to directly stimulate directed movement of
cells. Whether a particular protein has chemotactic activity for a population of cells can be
readily determined by employing such protein or peptide in any known assay for cell
2 0 chemotaxis.
The activity of a protein of the invention may, among other means, be measured by the
following methods:
Assays for chemotactic activity (which will identify proteins that induce or prevent
chemotaxis) consist of assays that measure the ability of a protein to induce the migration of
2 5 cells across a membrane as well as the ability of a protein to induce the adhesion of one cell
population to another cell population. Suitable assays for movement and adhesion include,
without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan,
A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing
Associates and Wiley-Interscience (Chapter 6.12, Mea~ul~,llcnl of alpha and beta Chçmf kinf~s
6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS
103: 140-146, 1995; Muller et al Eur. J. Immunol. 2~: 1744-1748; Gruber et al. J. of Imrnunol.
152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.
Hemostatic and Thrombolytic Activity
CA 02262401 1999-02-01
W O 98/05781 PCTrUS97113603
A protein of the invention may also exhibit hemostatic or thrombolytic activity. As
a result, such a protein is expected to be useful in treatment of various coagulation disorders
(including hereditary disorders, such as hemophilias) or to enhance coagulation and other
hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein
5 of the invention may also be useful for dissolving or inhibiting formation of thromboses and
for treatment and prevention of conditions resulting therefrom (such as, for example, infarction
of cardiac and central nervous system vessels (e.g., stroke).
The activity of a protein of the invention may, among other means, be measured by the
following methods:
Assay for hemostatic and thrombolytic activity include, without limitation, those
described in: Linet et al., J. Clin. Pharrnacol. 26:131-140, Ig86; Burdick et al., Thrombosis
Res. 45:413-419, lg87; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins
35:467-474, 1988.
ReceptorlLi~and Activity
A protein of the present invention may also demonstrate activity as receptors, receptor
ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors
and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases
and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell
2 0 interactions and their ligands (including without limitation, cellular adhesion molecules ~such
as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen
presentation, antigen recognition and development of cellular and humoral immune responses).
Receptors and ligands are also useful for screening of potential peptide or small molecule
inhibitors of the relevant receptor/ligand interaction. A protein of the present invention
2 5 (inclLl-ling, without limitation, fragments of receptors and ligands) may themselves be useful
as inhibitors of receptor/ligand interactions.
The activity of a protein of the invention may, among other means, be measured by the
following methods:
Suitable assays for receptor-ligand activity include without limitation those described
3 0 in:Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies,
E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience
(Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22),
Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med.
168:1145-1156, 1988;Rosenstein etal., J.Exp.Med.169:149-160 1989; Stoltenborget
35 al., J. Im~nunol. Methods 175:59-68, lg94; Stitt et al., Cell 80:661-670, 1995.
CA 02262401 1999-02-01
WO 98tO5781 PCT/US97/13603
Anti-~nflammatory Activity
Proteins of the present invention may also exhibit anti-infl~mm~ory activity. The anti-
infl~mm~tf)ry activity may be achieved by providing a stimulus to cells involved in the
infl~mm~tory response, by inhibiting or promoting cell-cell interactions (such as, for example,
5 cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory
process, inhibiting or promoting cell extravasation, or by stim~ ting or ~u~ e~ lg production
of other factors which more directly inhibit or promote an infl~mm~ory response. Proteins
exhibiting such activities can be used to treat infl;lmm~lory conditions including chronic or
acute conditions), including without limitation inflammation associated with infection (such
10 as septic shock, sepsis or systemic infl~mm~tory response syndrome (SIRS)), ischemia-
reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection,
nephritis, cytokine or chemokine-induced lung injury, infl~mm~tory bowel disease, Crohn's
disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the
invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance
15 or material.
Tumor Inhibition Activity
In addition to the activities described above for immunological treatment or prevention
of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may
2 0 inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may
exhibit its tumor inhibitory activity by acting on turnor tissue or tumor precursor tissue, by
inhibiting forrnation of tissues necessary to support tumor growth ~such as, for example, by
inhibiting angiogenesis), by causing production of other factors, agents or cell types which
inhibit tumor growth, or by ~u~Jles~hlg, elimin~ting or inhibiting factors, agents or cell types
2 5 which promote tumor growth.
Other Activities
A protein of the invention may also exhibit one or more of the following additional
3 0 activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents,
including, without limitation, bacteria, viruses, fungi and other p,~a~ .s effecting (~ul)~le~sing
or enhancing) bodily characteristics, including, without limitation, height, weight, hair color,
eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape
(such as, for example, breast au~ ent~ion or diminution, change in bone form or shape);
3 5 effecting biorhythms or caricadic cycles or rhythms; effecting the fertility of male or female
24
CA 02262401 1999-02-01
WO 98/05781 PCT/US97113603
subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or
elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other
nutritional factors or component(s); effecting behavioral characteristics, including, without
limitation, appetite, iibido, stress, cognition (including cognitive disorders), depression
5 (including depressive disorders) and violent behaviors; providing analgesic effects or other
pain reducing effects; promoting difr~ellliation and growth of embryonic stem cells in lineages
other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes,
correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of
hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity
10 (such as, for example, the ability to bind antigens or complement); and the ability to act as an
antigen in a vaccine composition to raise an immune response against such protein or another
material or entity which is cross-reactive with such protein.
15 ADMINISTRATION AND DOSING
A protein of the present invention (from whatever source derived, including without
limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical
composition when combined with a pharmaceutically acceptable carrier. Such a composition
may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers,
20 solubilizers, and other materials well known in the art. The term "pharmaceutically
acceptable" means a non-toxic material that does not interfere with the effectiveness of the
biological activity of the active ingredient(s). The char~rtçri~tics of the carrier will depend on
the route of ~-lminictration. The pharm~eutic~l composition of the invention may also contain
cytokines, Iymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, L-1,
25 ~L-2, IL-3, IL-4, L-S, L-6, IL-7, L-8, IL-9, L-10, IL-11, IL-12, L-13, IL-14, IL-I~, ~N,
TNF0, TNFI, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem oell factor, and erythropoietin.
The pharmaceutical composition may further contain other agents which either enhance the
activity of the protein or compliment its activity or use in treatment. Such additional factors
and/or agents may be included in the ph;~ aoeuLical composition to produce a synergistic
3 0 effect with protein of the invention, or to minimi7P side effects. Conversely, protein of the
present invention may be included in formulations of the particular cytokine, Iymphokine, other
hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-infl~mm~ory agent to
minimize side effects of the cytokine, Iymphokine, other hematopoietic factor, thrombolytic
or anti-thrombotic factor, or anti-infl~mm~ory agent.
CA 02262401 1999-02-01
WO 98/0~781 PCT/US97/13603
A protein of the present invention may be active in multimers (e.g., heterodimers or
homodimers) or complexes with itself or other proteins. As a result, pharrnaceutical
compositions of the invention may comprise a protein of the invention in such multimeric or
complexed form.
5The pharrnaceutical composition of the invention may be in the form of a complex of
the protein(s) of present invention along with protein or peptide antigens. The protein and/or
peptide antigen will deliver a stim~ t~nry signal to both B and T Iymphocytes. B Iymphocytes
will respond to antigen through their surface immunoglobulin receptor. T Iymphocytes will
respond to antigen through the T cell receptor (TCR) following presentation of the antigen by
1 0MHC proteins. MHC and structurally related proteins including those encoded by class I and
class II MHC genes on host cells will serve to present the peptide antigen(s) to T Iymphocytes.
The antigen components could also be supplied as purified MHC-peptide complexes alone or
with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able
to bind surface immunolgobulin and other molecules on B cells as well as antibodies able to
15bind the TCR and other molecules on T cells can be combined with the pharmaceutical
composition of the invention.
The ph~rm~re~ltical composition of the invention may be in the form of a liposome in
which protein of the present invention is combined, in addition to other pharmaceutically
acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as
2 0micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable
lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides,
sulfatides, Iysolecithin, phospholipids, saponin, bile acids, and the like. ~lepdl~lion of such
liposomal formulations is within the level of skill in the art, as disclosed, for example. in U.S.
Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent
2 5No. 4,737,323, a}l of which are incorporated herein by reference.
As used herein, the term ''~ al~ul;c~lly effective amount" means the total amount of
each active component of the pharm~re~ir~l composition or method that is sufficient to show
a mr~ningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant
medical condition, or an increase in rate of tr~tment, healing, prevention or amelioration of
3 0such conditions. When applied to an individual active ingredient, ~lminict~red alone, the term
refers to that ingredient alone. When applied to a combination, the term refers to combined
amounts of the active ingredients that result in the therapeutic effect, whether ;lflministrred in
combination, serially or simultaneously.
In practicing the method of ll~ll"el,~ or use of the present invention, a therapeutically
3 5effective amount of protein of the present invention is administered to a m~mm~l having a
26
CA 02262401 1999-02-01
W O 98/05781 PCTrUS97113603
condition to be treated. Protein of the present invention may be administered in accordance
with the method of the invention either alone or in combination with other therapies such as
treatments employing cytokines, Iymphokines or other hematopoietic factors. When co-
~flmini~tered with one or more cytokines, Iymphokines or other hematopoietic factors, protein
5 of the present invention may be administered either simultaneously with the cytokine(s),
Iymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or
se~uentially. If a-lminict~red sequentially, the attending physician will decide on the
appropriate sequence of administering protein of the present invention in combination with
cytokine(s), Iymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic
1 0 factors.
Administration of protein of the present invention used in the pharrnaceutical
composition or to practice the method of the present invention can be carried out in a variety
of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous,
subcutaneous, hl~ oneal, parenteral or intravenous injection. Intravenous administration
15 to the patient is preferred.
When a therapeutically effective amount of protein of the present invention is
administered orally, protein of the present invention will be in the form of a tablet, capsule,
powder, solution or elixir. When :~rlminict~red in tablet form, the pharmaceutical composition
of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The
2 0 tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and
preferably from about 25 to 90% protein of the present invention. When ~ d in liquid
form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil,
mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the
pharmaceutical composition may further contain physiological saline solution, dextrose or
2 5 other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene
glycol. When ~ e.~d in liquid form, the pharm~reutic~l composition contains from
about 0.5 to 90% by weight of protein of the present invention, and preferably from about I
to 50% protein of the present invention.
When a therapeutically effective amount of protein of the present invention is
3 0 ~flmini$tered by intravenous, cutaneous or subcutaneous injection, protein of the present
invention will be in the forrn of a pyrogen-free, p~c~ lally acceptable aqueous solution. The
pl~a~lion of such p~ntelally acceptable protein solutions, having due regard to pH,
isotonicity, stability, and the like, is within the skill in the art. A preferred ph~rm~relltic~l
composition for intravenous, ~;ul~eous, or sllh~ ;...e~,us injection should contain, in addition
3 5 to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection,
27
CA 02262401 1999-02-01
W O 98/05781 PCT~US97tl3603
Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated
Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of
the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other
additives known to those of skill in the art.
The amount of protein of the present invention in the pharrnaceutical composition of
the present invention will depend upon the nature and severity of the condition being treated,
and on the nature of prior treatments which the patient has undergone. Ultimately, the
~tenrling physician will decide the amount of protein of the present invention with which to
treat each individual patient. Initially, the ~nl nfling physician will administer low doses of
protein of the present invention and observe the patient's response. Larger doses of protein of
the present invention may be administered until the optimal therapeutic effect is obtained for
the patient, and at that point the dosage is not increased further. It is contemplated that the
various pharmaceutical compositions used to practice the method of the present invention
should contain about 0.01 llg to about 100 mg (preferably about O. l ,ug to about l O mg, more
preferably about 0.1 llg to about I mg) of protein of the present invention per kg body weight.
The duration of intravenous therapy using the pharmaceutical composition of the
present invention will vary, depending on the severity of the disease being treated and the
condition and potential idiosyncratic response of each individual patient. It is contemplated
that the duration of each application of the protein of the present invention will be in the range
2 0 of 12 to 24 hours of continuous intravenous administration. Ultimately the at~.nfling physician
will decide on the appropriate duration of intravenous therapy using the pharmaceutical
composition of the present invention.
Protein of the invention may also be used to immllni7~ animals to obtain polyclonal
and monoclonal antibodies which specifically react with the protein. Such antibodies may be
2 5 obtained using either the entire protein or fragments thereof as an immunogen. The peptide
immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are
conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing
such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85,
2149-2154 (1963); J.L. KrstPn~nclry~ et ~zl., FEBS Lett. 211, 10 (1987). Monoclonal
3 0 antibodies binding to the protein of the invention may be useful diagnostic agents for the
immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein
may also be useful the-dl)eulics for both conditions associated with the protein and also in the
Llc~dllllent of some forrns of cancer where abnormal expression of the protein is involved. In
the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the
CA 02262401 1999-02-01
WO 98/OS781 PCTlUS97tl3603
protein may be useful in detecting and preventing the metastatic spread of the cancerous cells,
which may be mediated by the protein.
For compositions of the present invention which are useful for bone, cartilage, tendon
or ligament regeneration, the therapeutic method includes administering the composition
5 topically, systematically, or locally as an implant or device. When administered, the
therapeutic composition for use in this invention is, of course, in a pyrogen-free,
physiologically acceptable form. Further, the composition may desirably be encapsulated or
injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical
administration may be suitable for wound healing and tissue repair. Therapeutically useful
10 agents other than a protein of the invention which may also optionally be included in the
composition as described above, may alternatively or additionally, be ~ nicteredsimultaneously or sequentially with the composition in the methods of the invention.
Preferably for bone and/or cartilage forrnation, the composition would include a matrix capable
of delivering the protein-containing composition to the site of bone and/or cartilage damage,
15 providing a structure for the developing bone and cartilage and optimally capable of being
resorbed into the body. Such matrices may be formed of materials presently in use for other
implanted medical applications.
The choice of matrix material is based on biocompatibility, biodegradability,
mechanical properties, cosmetic appearance and interface properties. The particular
2 0 application of the compositions will define the appropriate formulation. Potential matrices for
the compositions may be biodegradable and chemically defined calcium sulfate,
tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides.
Other potential materials are biodegradable and biologically well-defined, such as bone or
dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix
2 5 components. Other potential matrices are nonbiodegradable and chemically defined, such as
sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised
of c- mhinzl~ions of any of the above mentioned types of m:~teri:~l, such as polylactic acid and
hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in
composition, such as in calcium-~lumin~te-phosphate and processing to alterpore size, particle
3 0 size, particle shape, and biodegradability.
Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid
in the form of porous particles having diameters ranging from l 50 to 800 microns. In some
applications, it will be useful to utilize a seqnesrering agent, such as carboxymethyl cellulose
or autologous blood clot, to prevent the protein compositions from disassociating from the
3 5 matrix.
29
CA 0226240l l999-02-Ol
W O98/05781 PCTAUS97tl3603
A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses
(including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose,
hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and
carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose
(CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate,
poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol).
The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on
total formulation weight, which represents the amount necessary to prevent desorbtion of the
protein from the polymer matrix and to provide appropriate handling of the composition, yet
not so much that the progenitor cells are prevented from infiltrating the matrix, thereby
providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.
In further colllpo~ilions, proteins of the invention may be combined with other agents
beneficial to the treatment of the bone andlor cartilage defect, wound, or tissue in question.
These agents include various growth factors such as epidermal growth factor tEGF), platelet
derived growth factor (PDG~), transforrning growth factors (TGF-a and TGF-~), and insulin-
like growth factor (IGF).
The therapeutic compositions are also presently valuable for veterinary applications.
Particularly domestic animals and thoroughbred horses, in addition to humans, are desired
patients for such treatment with proteins of the present invention.
2 0 The dosage regimen of a protein-containing pharmaceutical composition to be used
in tissue regeneration will be determined by the att~n~ling physician considering various factors
which modify the action of the proteins, e.g., arnount of tissue weight desired to be formed, the
site of damage, the condition of the rl~ms~ged tissue, the size of a wound, type of damaged
tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of
2 5 :l~1mini~tration and other clinical factors. The dosage may vary with the type of matrix used
in the ~c~cons~ilulion and with inclusion of other proteins in the pharmaceutical composition.
For example, the addition of other known growth factors, such as IGF I (insulin like growth
factor I), to the final composition, may also effect the dosage. Progress can be monitored by
periodic :~sses~m~nt of tissue/bone growth and/or repair, for example, X-rays,
3 0 histomorphometric determinations and tetracycline labeling.
Polynucleotides of the present invention can also be used for gene therapy. Suchpolynucleotides can be introduced either in vivo or ex vivo into cells for expression in a
m~mm~ n subject. Polynucleotides of the invention may also be administered by other
known methods for introduction of nucleic acid into a cell or organism (including, without
3 5 limitation, in the form of viral vectors or naked DNA).
CA 02262401 1999-02-01
WO 98/05781 PCTIUS97/13603
Cells may also be cultured ex vivo in the presence of proteins of the present invention
in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells
can then be introduced in vivo for therapeutic purposes.
Patent and literature references cited herein are incorporated by reference as if fully
set forth.
CA 0226240l l999-02-0l
WO 9810~781 PCT/US97113603
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Jacobs, Kenneth
LaVallie, Edward
Racie, Lisa
Merberg, David
Treacy, Maurice
Spaulding, Vik~i
(ii) TITLE OF INVENTION: SECRETED PROTEINS AND POLYNUCLEOTIDES
ENCODING THEM
(iii) NUMBER OF SEQUENCES: 5
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Genetics Institute, Inc.
(B) STREET: 87 CambridgePark Drive
(C) CITY: Cambridge
(D) STATE: Massachusetts
(E) COUNTRY: U.S.A.
(F) ZIP: 02140
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
~B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Brown, Scott A.
(B) REGISTRATION NUMBER: 32,724
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (617) 498-8224
(B) TELEFAX: (617) 876-5851
(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 272 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
MOLECULE TYPE: cDNA
CA 02262401 1999-02-01
WO ~JU~ /~1 PCT~US97/13603
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
GCCAGCAGTT GTGCCAGCAG CATGCATCCA GCAGGGGTGC TAGGCAAAGA AAAGGTGGGT 60
TGAGGACAGG GCGTGTTCTC CGGGACTCTG TNAGCCACGA NGANGCTGCA ACACCANCCC 120
CANANCCTCC GGGAAATGGG GACTTCCANG ACCANCCACA GCCCCGGGGT GGGGACACTG 180
ACCCNGAGCT CACNAAATAA AGGCCGTCTT GCGGGTTTAT GATATCCTGG GTAACGGCAG 240
CCTTGGGGCT GTTTTTCAAN AAGCTTGCTC TT 272
(2~ INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 509 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
AGGAGAATTA GGACAGTTTT TCCTTCTGGC CGCAAGTACG GAGNGANTNA AAAATGTGAG 60
ACA~ Cll NGGCTGCAAA TNTGACTGAT TTCCATTTTA ANGAGAAAGT CCACATTTCT 120
GATCANACAT TTTTTCTTGT AAAGACAGAC TTAGGNGCTT TTCTCCTCTA T~ l~lG 180
GCATAATTTT TCATAAGGAA AGTATATTTA TGATATTTAC ATTAATATAA TTAATGTATA 240
TTTTATATTA GTAGCATATT AACAGTGTAA TAAAAAATAA AAACAAACTC TAGTATCCAG 300
AGGATCACAT GCTGACCAGA CCCTGTGTAG AAAGTGCCGA AGAGCATCAA GGAAATGGAA 360
ACGTTGGAAT TCCATCCGTG CTTGTGGCTT TCCTTAAACT TTTGTTATGG AAAATTTCAA 420
ATATACCCCG AAGTGGAGAT TGGCTTAAAT CAGCCCCACG TGCCCATCAC TCGGCTCCAG 480
TCATTATCCA GTGTGGTTCC TCTGATCTT 509
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 67 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
CA 0226240l l999-02-0l
W O 98/05781 PCTrUS97/13603
(ii) MOLECULE TYPE: protein
~xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Met Leu Thr Arg Pro Cys Val Glu Ser Ala Glu Glu His Gln Gly Asn
1 5 10 15
Gly Asn Val Gly Ile Pro Ser Val Leu Val Ala Phe Leu Lys Leu Leu
Leu Trp Lys Ile Ser Asn Ile Pro Arg Ser Gly Asp Trp Leu Lys Ser
Ala Pro Arg Ala His His Ser Ala Pro Val Ile Ile Gln Cys Gly Ser
50 55 60
Ser Asp Leu
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 264 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
TGGCAGCAAT GAGATCTGCT NTCTTAATTC TGTGCNGGGA AATCTTCNGG CGNGAATGGG 60
TTTGAGGCTT GAAACATNAC TTATATAAGT CACCTAAACN ACAAAACAAN GATTGGAGTA 120
AAAATTAATG CCATTTTTAT TTTAAGTATC AGATACCAGA TGATGCATGT CAACTAAGCT 180
TTTAGCTTTT CTTAAAAGAT GCAAAGGTTT CAAANCCAAA AATATTTAAT AAAAATAAAC 240
CCAACATAAA P~}~~~uUAAA AAAA Z64
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
34
CA 02262401 1999-02-01
WO 98/05781 PCT/US97/13603
(ii) MOLECULE TYPE: other nucleic acid
(A~ DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
ANAGTTTAAG GAAAGCCACA AGCACGGAT 29
